SENTI BIOSCIENCES INC (SNTI) Stock Price, Quote, News and Overview
NASDAQ:SNTI - Nasdaq - US81726A2096 - Common Stock - Currency: USD
SNTI Quote, Performance and Key Statistics
5
+0.13 (+2.67%)
The current stock price of SNTI is 5 USD. In the past month the price increased by 50.34%. In the past year, price increased by 72.41%.
SNTI Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.12 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 323.56 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About SNTI
Company Profile
Senti Biosciences, Inc. is a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 34 full-time employees. The company went IPO on 2021-05-26. The company is developing cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. The company is focused on off-the-shelf CAR-NK cell therapy programs for oncology indications. Its lead product candidate, SENTI-202, is a potential Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively target and eliminate CD33 and/or FLT3 expressing hematologic malignancies, including acute myeloid leukemia, while sparing healthy bone marrow cells. Its second clinical development program is SENTI-301A, a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy. SENTI-202 has been designed to incorporate three chimeric proteins using a Logic Gated gene circuit and delivered through a single retrovirus. SENTI-301A is a multi-armed off-the-shelf healthy donor derived CAR-NK cell therapy designed for the treatment of advanced GPC3 positive tumors.
Company Info
SENTI BIOSCIENCES INC
2 Corporate Drive, First Floor
South San Francisco CALIFORNIA US
Employees: 48
Company Website: https://www.sentibio.com/
Investor Relations: https://investors.sentibio.com/
Phone: 16503823281
SENTI BIOSCIENCES INC / SNTI FAQ
What is the stock price of SENTI BIOSCIENCES INC today?
The current stock price of SNTI is 5 USD. The price increased by 2.67% in the last trading session.
What is the ticker symbol for SENTI BIOSCIENCES INC stock?
The exchange symbol of SENTI BIOSCIENCES INC is SNTI and it is listed on the Nasdaq exchange.
On which exchange is SNTI stock listed?
SNTI stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SENTI BIOSCIENCES INC stock?
7 analysts have analysed SNTI and the average price target is 12.24 USD. This implies a price increase of 144.8% is expected in the next year compared to the current price of 5. Check the SENTI BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SENTI BIOSCIENCES INC worth?
SENTI BIOSCIENCES INC (SNTI) has a market capitalization of 130.00M USD. This makes SNTI a Micro Cap stock.
How many employees does SENTI BIOSCIENCES INC have?
SENTI BIOSCIENCES INC (SNTI) currently has 48 employees.
What are the support and resistance levels for SENTI BIOSCIENCES INC (SNTI) stock?
SENTI BIOSCIENCES INC (SNTI) has a support level at 3.03 and a resistance level at 5.18. Check the full technical report for a detailed analysis of SNTI support and resistance levels.
Is SENTI BIOSCIENCES INC (SNTI) expected to grow?
The Revenue of SENTI BIOSCIENCES INC (SNTI) is expected to grow by 78.57% in the next year. Check the estimates tab for more information on the SNTI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SENTI BIOSCIENCES INC (SNTI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SNTI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SNTI, evaluating the profitability, health, valuation and growth aspects
- SENTI BIOSCIENCES INC (SNTI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SENTI BIOSCIENCES INC (SNTI) Sales and EPS estimates to see what analysts future expectations are.
- SENTI BIOSCIENCES INC (SNTI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SENTI BIOSCIENCES INC (SNTI) Insider and Institutional Ownership to learn about the owners and their transactions.
- SENTI BIOSCIENCES INC (SNTI) Stock Chart to make your own analysis
- SENTI BIOSCIENCES INC (SNTI) Latest news and press-releases to stay up to date.
Does SENTI BIOSCIENCES INC (SNTI) stock pay dividends?
SNTI does not pay a dividend.
What is the Price/Earnings (PE) ratio of SENTI BIOSCIENCES INC (SNTI)?
SENTI BIOSCIENCES INC (SNTI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.54).
What is the Short Interest ratio of SENTI BIOSCIENCES INC (SNTI) stock?
The outstanding short interest for SENTI BIOSCIENCES INC (SNTI) is 0.56% of its float. Check the ownership tab for more information on the SNTI short interest.
SNTI Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to SNTI. When comparing the yearly performance of all stocks, SNTI is one of the better performing stocks in the market, outperforming 95.58% of all stocks.
SNTI Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SNTI. The financial health of SNTI is average, but there are quite some concerns on its profitability.
SNTI Financial Highlights
Over the last trailing twelve months SNTI reported a non-GAAP Earnings per Share(EPS) of -11.54. The EPS decreased by -115.47% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -53.95% | ||
| ROE | -104.01% | ||
| Debt/Equity | 0 |
SNTI Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 83% to SNTI. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 87.07% and a revenue growth 78.57% for SNTI